OPTOMYCIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTOMYCIN (OPTOMYCIN).
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
| Metabolism | Optomycin is not significantly metabolized. It is primarily eliminated unchanged in the urine via glomerular filtration. Does not undergo hepatic metabolism; no known CYP450 interactions. |
| Excretion | Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%. |
| Half-life | 3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment. |
| Protein binding | 30-40% bound to serum albumin. |
| Volume of Distribution | 0.5-0.8 L/kg; indicates distribution into extracellular fluid. |
| Bioavailability | IM: 90-100%; Oral: <5% (not therapeutically relevant). |
| Onset of Action | IV: 30-60 min; IM: 1-2 hours; Oral: not applicable (poor absorption). |
| Duration of Action | 6-8 hours for IV/IM; bacteriostatic effects persist up to 12 hours post-peak. |
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | CrCl 30-59 mL/min: 1.5 mg/kg IV every 12-24 hours; CrCl 10-29 mL/min: 1.5 mg/kg IV every 24-48 hours; CrCl <10 mL/min: 1.5 mg/kg IV every 48-72 hours. Consider therapeutic drug monitoring. |
| Liver impairment | No dose adjustment required for Child-Pugh A, B, or C. Use with caution in severe hepatic impairment due to potential nephrotoxicity risk. |
| Pediatric use | Neonates: 4 mg/kg IV every 12 hours (postnatal age <7 days) or every 8 hours (7-28 days). Infants and children: 2.5 mg/kg IV every 8 hours. Maximum single dose 100 mg. |
| Geriatric use | Start at lower end of dosing range (e.g., 1-1.5 mg/kg IV every 12-24 hours) based on renal function. Monitor serum creatinine and drug levels closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPTOMYCIN (OPTOMYCIN).
| Breastfeeding | Limited human data; M/P ratio unknown. Aminoglycosides are poorly excreted into breast milk. Risk of infant gut microbiome alteration and theoretical ototoxicity; use with caution during breastfeeding. |
| Teratogenic Risk | First trimester: No adequate human data; animal studies show no teratogenic effects at clinically relevant doses. Second trimester: Risk of fetal ototoxicity if maternal aminoglycoside levels exceed therapeutic range. Third trimester: Potential for fetal renal and auditory toxicity; avoid use unless essential. |
■ FDA Black Box Warning
WARNING: NEPHROTOXICITY AND OTOTOXICITY - Optomycin can cause acute kidney injury and irreversible sensorineural hearing loss. Monitor renal function and auditory function before and during therapy. Avoid concurrent use of other nephrotoxic or ototoxic agents.
| Serious Effects |
Hypersensitivity to optomycin or other glycopeptides (e.g., vancomycin, teicoplanin). Preexisting severe hearing loss or renal impairment (unless benefits outweigh risks). Concomitant use of other known nephrotoxic or ototoxic drugs (e.g., aminoglycosides, loop diuretics, cisplatin) unless absolutely necessary and with close monitoring.
| Precautions | Monitor renal function (serum creatinine, BUN, urinalysis) at baseline and regularly during therapy; adjust dose based on creatinine clearance. Perform audiometric testing at baseline and weekly during prolonged therapy. Risk of ototoxicity increased with high trough levels (>20 mg/L). Use with caution in patients with pre-existing renal impairment, hearing loss, or those receiving concomitant nephrotoxic agents. May cause red man syndrome (histamine release) if infused too rapidly; premedicate with antihistamines if needed. Neurotoxicity including optic neuropathy and peripheral neuropathy reported. Monitor for Clostridium difficile-associated diarrhea. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal serum drug levels (peak and trough); assess renal function (serum creatinine, BUN); monitor fetal growth and amniotic fluid volume via ultrasound; perform neonatal auditory screening after delivery. |
| Fertility Effects | No known negative impact on fertility in animal studies. Human data insufficient. |